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Insufficient knowledge of etiology and 
pathophysiology of depression
ood Disorders (MD), particularly major
depression,have been estimated to be the fourth major
cause of disability worldwide,and may become second
only to cardiovascular diseases in the next two decades.
1
A recent consensus document by the European Brain
Council estimated the annual cost of MD at 106 billion
EUR,with a prevalence of 21 million people across 28
European countries.
2 Less that 50% of all patients treated
with the currently available antidepressants show full
remission. However, despite the clear need for better
therapies,recent efforts to develop novel antidepressants
have been relatively unsuccessful (for discussion see ref
3).A main reason for this is the still-incomplete knowl-
edge of the pathogenetic mechanisms of depression and
understanding of antidepressant mechanisms. At the
same time, although several animal models have been
developed,a model that replicates the etiological factors
causing depression in humans, and consequently the
symptoms as well,is lacking.
4An analysis of the present
knowledge of the pathogenetic mechanisms of depres-
sion is beyond the scope of this article; therefore this
issue will only be briefly addressed when necessary.The
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The hypotheses on the pathophysiology of depression
/mood disorders and on antidepressant mechanisms have
greatly changed in recent years. The classical monoamine
hypothesis was revealed to be simplistic, in that it could
not explain the temporal delay in the therapeutic action
of antidepressants. Converging lines of evidence have
shown that adaptive changes in the several mechanisms
of neuroplasticity are likely to be the cellular and molec-
ular correlates of therapeutic effect. In this article, several
mechanisms of neuroplasticity are analyzed in relation to
the mechanism of antidepressants, ranging from changes
in gene expression (including neurotrophic mechanisms),
to synaptic transmission and plasticity, and neurogene-
sis. We propose that the current version of the hypothe-
sis of antidepressant mechanism simply be called the
“hypothesis of neuroplasticity.” In the final section, we
also briefly review the main current novel strategies in the
pharmacology of depression and the new putative targets
for antidepressants, with particular emphasis on non-
monoaminergic mechanisms.
© 2008, LLS SAS Dialogues Clin Neurosci. 2008;10:385-400.main goal of this work is an update of current knowledge
of mechanisms of antidepressant drugs,with particular
relevance to neuroplasticity.For this purpose,in the fol-
lowing paragraph we report a brief pharmacological clas-
sification of currently available antidepressants,based on
their primary mechanism of action.Then,we will address
the evolutionary process of antidepressants and relevant
pharmacological research,from the first version of the
monoamine hypothesis to the present hypothesis of neu-
roplasticity.With regard to the present knowledge of neu-
roplasticity mechanisms we will analyze how antidepres-
sants impact on distinct levels of these mechanisms,
ranging from postreceptor signaling cascades to the reg-
ulation of gene expression and synaptic mechanisms.
Finally,we will briefly analyze future directions in psychi-
atric pharmacological research and possible strategies for
exploring new targets for antidepressants.
Currently available antidepressants
Brief classification of antidepressants
We arbitrarily classify antidepressants into first- and sec-
ond-generation drugs (Figure 1).First-generation antide-
pressants (FGAs) include monoamine oxidase inhibitors
(MAOIs) and tricyclic antidepressants (TCAs), which
became available for therapy in the 1960s.MAOIs,such
as iproniazide or tranylcypromine, are irreversible
inhibitors of the main metabolic enzymes of the
monoamine neurotransmitters noradrenaline (NA),sero-
tonin (5-HT),and dopamine (DA),and result in a gener-
alized increase of monoamine levels throughout the cen-
tral nervous system (CNS).
5,6 MAOIs are powerful drugs
as to their therapeutic efficacy,but their use has been lim-
ited by the pronounced and potentially lethal adverse
effects, including hypertensive potential. TCAs, intro-
duced shortly after MAOIs, are a variegated class of
drugs,named after their chemical structure derived from
phenothiazines, including such drugs as imipramine,
clomipramine,and amitriptyline.The main pharmacolog-
ical mechanism of TCAs is the inhibition of membrane
transporters for the monoamines,with more or less selec-
tivity, changing from one to the other.TCA treatment
results in increased extracellular availability of
monoamine neurotransmitters.These are also efficient
drugs,and have represented the mainstay of pharmaco-
logical therapy of depression for decades,although char-
acterized by a wide profile of adverse effects, mainly
owing to variable antagonism for muscarinic,adrenergic,
and histaminergic receptors.The mechanism of MAOIs
and TCAs represented the main evidence for the
monoamine hypothesis of depression and MD,an intrin-
sically tautological hypothesis which,nevertheless,has
driven pharmacological research on depression for over
four decades.
7,8
Second-generation antidepressants (SGAs) include sev-
eral different classes of drugs that were developed mainly
in the 1980s and 1990s,starting with selective serotonin
reuptake inhibitors (SSRIs) and including serotonin and
noradrenaline reuptake inhibitors (SNRIs),noradrena-
line reuptake inhibitors (NARIs),noradrenergic and spe-
cific serotonergic antidepressants (NaSSAs) and 5-HT2A
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Selected abbreviations and acronyms
AMPA alpha-amino-3-hydroxy-5-methyl-4-isoxazolepro-
pionic acid
BDNF brain-derived neurotrophic factor
CREB cAMP-response element binding protein
LTP long-term potentiation
MAOI monoamine oxidase inhibitor
NMDA N-methyl-D-aspartic acid
SNRI serotonin and noradrenaline reuptake inhibitor
SSRI selective serotonin reuptake inhibitor
TCA tricyclic antidepressant
Figure 1. Main classes of antidepressant drugs from the 1960s to present
times. FGA, first-generation antidepressant; SGA, second-gen-
eration antidepressant; TGA, third-generation antidepressant
(only the main classes of antidepressants in development are
reported among TGAs, see also Table III). MAOI, monamine oxi-
dase inhibitor; SSRI, selective serotonin reuptake inhibitor; SNRI,
serotonin and noradrenaline reuptake inhibitor; NARI, noradren-
aline reuptake inhibitor; SARI, serotonin 2A antagonist/ reuptake
inhibitor; NASSA, noradrenergic and specific serotonergic anti-
depressant; MT, melatonin; 5-HT, serotonin; NK, neurokinin; CRF,
corticotropin-releasing factor; Glu, glutamate
Classes of antidepressants
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Efficacy
Tolerability, safety
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2000santagonists/ reuptake inhibitors (SARIs).All the SGAs
are based on the monoamine hypothesis,with a primary
mechanism consisting of monoamine reuptake inhibition
and/or antagonism for selected monoamine receptor(s).
SSRIs,including fluoxetine,sertraline,paroxetine,fluvox-
amine,citalopram,and the recent addition escitalopram,
have largely been substituted for TCAs in clinical ther-
apy,owing to a more favorable profile of adverse effects.
SNRIs (venlafaxine and duloxetine), NaSSAs (mainly
mirtazapine),and NARIs (reboxetine) are also consid-
ered as primary choices for treatment of depression.
However, although most of the SGAs are superior to
TCAs with regard to adverse effects,none of them has
offered a substantial improvement in efficacy over TCAs,
and SGAs are considered at best comparable to TCAs in
this respect (Figure 1).For a detailed discussion on the
mechanism of action of the different drug classes see ref
8. Finally, in our classification we call third-generation
drugs (TGAs) novel compounds that are in most cases
characterized by nonmonoaminergic mechanisms
(although some of these have been in development for
quite a while).TGAs will be analyzed in the last chapter
of this article,dealing with new targets for the develop-
ment of antidepressants.
Monoamine hypothesis of depression: inconsistencies
As addressed above, the monoamine hypothesis of
depression and mood disorders was mainly based on the
mechanism itself of the first antidepressant drugs,
MAOIs and TCAs.Additional evidence was based on the
prodepressive effect of the antihypertensive reserpine,
which depletes storage vesicles containing noradrenaline
and other monoamines.The basic version of the hypoth-
esis stated that depression was due to reduced availabil-
ity of monoamines,particularly noradrenaline and sero-
tonin,and that antidepressants exerted their therapeutic
action by increasing the extracellular availability of
monoamines,particularly at synaptic level.
9 However,the
hypothesis was soon criticized because it was evident that
increased availability of monoamines,due to inhibition
of reuptake or metabolism, developed in a matter of
hours,could not be the direct mechanism of the thera-
peutic effect, which develops only after several weeks.
Therefore,in the following decades,with the progress of
pharmacological research, updated versions of the
hypothesis have followed,as schematized in the follow-
ing section.
Evolution of antidepressants
The monoamine hypothesis has much evolved from the
1960s to present times, along with the revolutionary
changes that have affected the neurosciences (Table I).
Part of the increased knowledge of intracellular, gene
expression,and synaptic mechanisms has been incorpo-
rated into the hypothesis,contributing to building up its
present version. However, it is the opinion of these
authors that pharmacological research on psychiatric dis-
orders has still insufficiently taken advantage of the
translational opportunities offered by the present state
of neuroscience research,and that this is one of the rea-
sons for the present lack of new drugs in psychiatry (for
a discussion of this issue see refs 3,10).
In order to explain the discrepancy between the timing
of the primary pharmacological action of antidepressants
and therapeutic effect,early changes to the monoamine
hypothesis took into account the sensitivity of
monoamine receptors. It was shown that a consistent
change induced by TCAs was the desensitization of the
β-adrenoceptor,and consequently it was suggested that
changes in the sensitization state of this and other recep-
tors,rather than increased monoamine availability per se,
was a correlate of therapeutic efficacy.
11,12 In parallel,it
was suggested that the sensitivity of monoamine recep-
tors was also involved in the pathophysiology of depres-
sion. The most refined example of this stage of the
hypothesis was the explanation of the action of SSRIs,
largely based on a number of studies by the de Montigny
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• Monoaminergic hypothesis (1960s-1970s)
Depression is caused by a decreased availability of monoaminer-
gic neurotransmitters. Antidepressants boost monoamine levels
• Monoaminergic receptor hypothesis (1980s)
Depression is caused by abnormalities in monoamine receptors. 
Chronic antidepressants alter sensitization state of receptors
• Hypothesis of signaling adaptation (1990s)
Chronic antidepressants induce adaptive changes in postreceptor 
signaling cascades, and in gene expression
• Hypothesis of neuroplasticity (2000s)
Chronic antidepressants change neuroplasticity, cellular resilience, 
and synaptic plasticity
Table I. Evolution of hypotheses on the pathophysiology/pharmacother-
apy of mood disorders.


group,with the opposite changes induced by acute and
chronic drug treatment in the sensitization of 5-HT1A
receptors and consequently in the firing rate of seroton-
ergic neurons originating in the raphe nuclei.
7This evi-
dence-based scheme proposed that desensitization of 5-
HT1A receptors and increased firing rate of serotonergic
neurons during treatment was a correlate of therapeutic
action. However, although satisfactory for SSRIs, this
framework could not explain the action of other antide-
pressants.Additionally,the time required for the recep-
tor sensitivity changes was still not long enough to
account for the several weeks required for the onset of
action of most antidepressants.At the same time,during
the 1980s,the knowledge of postreceptor signaling mech-
anisms was progressing at a fast pace.Once these mech-
anisms were understood and described better,it was pro-
posed that slow adaptive changes in postreceptor
signaling cascades and downstream mechanisms could be
more appropriate mediators of the delayed action of
antidepressants,
13 with changes in gene expression repre-
senting plausible downstream effectors of this action
(Table I).The present and updated version of the hypoth-
esis, which we call the “hypothesis of neuroplasticity,”
integrates postreceptor intracellular signaling cascades
with the mechanisms of gene expression (including epi-
genetic mechanisms) and several other processes,includ-
ing synaptic mechanisms,neurotrophic mechanisms,and
neurogenesis.We think this is the best definition at pre-
sent,because neuroplasticity nicely encompasses all the
mechanisms that have been linked to the action of anti-
depressants (including neurotrophic pathways). See
Table II for a definition of molecular/cellular neuroplas-
ticity.An important corollary of this hypothesis is that
neuroplasticity can be advantageous,such as that induced
by some antidepressants,
14 but can also be maladaptive,
such as that recorded in human brain studies with
depressed patients or in animal models of stress and
mood disorders.
15-17 An additional interesting concept,
which is also receiving experimental validation, is that
maladaptive plasticity contextual to the pathological state
can at least partly be reversed by antidepressant treat-
ments.
18
Mechanisms of neuroplasticity and 
the action of antidepressants
What is the meaning of neuroplasticity? Neurobiologists
call neuroplasticity the complex of the several processes
whereby the brain senses,adapts,and responds to exter-
nal and internal stimuli of various nature.We address
here only molecular and cellular forms of neuroplastic-
ity,which can be both structural and functional in nature;
the manifestations of neuroplasticity under both these
respects can assume many forms.We have schematically
divided these forms into three major categories (listed in
Table II):(i) modifications of gene expression;(ii) mod-
ifications of synaptic transmission;(iii) neurogenesis.
Modifications of gene expression: the role of CREB
As addressed above,throughout the 1980s and 1990s the
research on the mechanism of antidepressants has moved
from the study of monoamine neurotransmitter levels
and sensitization state of membrane receptors to that of
postreceptor intracellular signaling pathways.It has been
shown that stimulation or inhibition of selected receptors
for serotonin and noradrenaline induces adaptive
changes in signaling pathways downstream of the recep-
tors,including extensive crosstalk between pathways.In
addition,many pathways are also activated by Ca
2+-chan-
nels, glutamate receptors, and receptors for neu-
rotrophins (Figure 2).A common downstream function
of these intracellular pathways is the regulation of gene
expression, through the activation of protein families
called transcription factors,that bind to specific domains
in the promoter region of genes and regulate mRNA
transcription.In this context,the most thoroughly stud-
ied factor, both in basic and psychopharmacological
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• Modifications of gene expression 
- Activation of signaling cascades 
- Activation of transcription factors 
- Epigenetic changes
- Activation/repression of different genes
• Modifications of synaptic transmission (synaptic plasticity) 
- Synaptogenesis 
- Alterations of dendritic function 
- Neurite extension 
- Synaptic remodeling 
- Long-term potentiation (LTP) 
- Long-term depression (LTD) 
• Neurogenesis
Table II. Major cellular/molecular manifestations of neuroplasticity in the
adult brain. Neuroplasticity is the complex of many processes
whereby the brain senses, adapts, and responds to external and
internal stimuli of various nature. Mechanisms of neuroplasticity in antidepressant action - Racagni and Popoli Dialogues in Clinical Neuroscience - Vol 10 . No.4 . 2008
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research,is the protein cAMP-response element binding
protein (CREB).CREB function is involved in a wide
range of brain mechanisms,including learning and mem-
ory,induction of neurotrophic programs,outgrowth of
neuronal processes,regulation of circadian rhythms,neu-
rogenesis,pathophysiology of neuropsychiatric and neu-
rodegenerative disorders, and mechanisms of psy-
chotropic drugs.
19-23 CREB is regulated in multiple ways,
including acetylation,ubiquitination,glycosylation,and
SUMOylation,but the best known form of regulation is
represented by phosphorylation at the Ser133 residue by
multiple protein kinases.
18,24-26There is general agreement
that chronic antidepressant treatments stimulate CREB
function,although different results have been reported
(see below).It has been shown that,rather than cAMP-
dependent pathways, other signaling cascades work as
major regulators of CREB function in the brain.In fact,
activity-dependent phosphorylation of CREB at Ser133
was shown to be induced in neurons by activation of the
Ras-mitogen activated protein (MAP) kinase and the
calcium/calmodulin (CaM)-dependent cascades
27-30 (for
discussion see ref 25).Furthermore,it was recently shown
that chronic antidepressant treatments significantly acti-
vate ERK-MAPK and CaM kinase IV cascades and at
Figure 2. Major signaling cascades involved in the activation of the transcription factor CREB and in the long-term action of antidepressants. A num-
ber of genes are depicted, whose transcription is regulated by CREB. Trk B, tyrosine kinase B; MAPK, mitogen-activated protein kinase; RSK,
ribosomal S6 kinase; CREB, cAMP response element binding protein; NMDA, N-methyl-D-aspartic acid; Glu, glutamate; PLC, phosphatase C;
PDE, phosphodiesterase; AC, adenylate cyclase; cAMP; cyclic adenosine monophosphate; ATP, adenosine triphosphate; PKA, protein kinase
A; TH, tyrosine hydroxylase; BDNF, brain-derived neurotrophic factor; AC-VIII, adenyl cyclase type VIII; CREm, CAMP-responsive element mod-
ulator; CRF, corticotropin-releasing factor, Syn, synaptopsin
Reproduced from ref 3: Carlezon WA Jr, Duman RS, Nestler EJ. The many faces of CREB. Trends Neurosci. 2005;28:436-445. Copyright © Elsevier 2005
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chronic lithium downregulates CREB phosphorylation
as well as CaM kinase IV expression and activation in
hippocampus.
31,32
By contrast,activation of CREB in the nucleus accum-
bens and other regions by substances of abuse or stress
mediates some aspects of drug addiction and depres-
sive/anxiety behaviors.
23 Other transcription factors of
primary importance, although less characterized com-
pared with CREB in the mechanism of antidepressants,
are the Fos family and NF-κB.
26
It has been suggested that activation of multiple signal-
ing cascades impinging on CREB is required for induc-
tion of persistent changes in gene expression.
33,34 This
mechanism could be a way of signaling stimuli of greater
significance,deserving to leave a more persistent trace in
gene expression and cellular function.We have recently
asked whether this notion may apply to the action of
antidepressants,by analyzing the time course of activa-
tion of multiple signaling cascades and of CREB phos-
phorylation after antidepressant treatments.Indeed,in
our experience CREB activation and expression of a
CREB-regulated gene (brain-derived neurotrophic fac-
tor,BDNF) seemed to be stronger when multiple signal-
ing cascades were activated early and at the same time
during treatments (Musazzi et al,unpublished material).
There are more than 100 identified genes regulated by
CREB.Among them are such diverse genes as tyrosine
hydroxylase (the rate-limiting enzyme in cathecolamine
biosynthesis),the GluR1 subunit of AMPA receptor for
glutamate,the presynaptic protein synapsin I,the neu-
ropeptide corticotropin releasing factor (CRF),BDNF,
and many others (Figure 2).
Modifications of gene expression: the role of BDNF
BDNF,along with its receptor TrkB,has been widely stud-
ied as a gene involved in the regulation of neuroplasticity
and cognition, as well as susceptibility to various neu-
ropsychiatric disorders, including Alzheimer’s disease,
schizophrenia, bipolar disorder, and attention deficit-
hyperactivity disorder. Among the CREB-regulated
genes,BDNF is by far the one most thoroughly studied
with regard to the mechanism of antidepressants and has
lately become,together with CREB activation,a sort of
readout system in the study of antidepressant mecha-
nisms.
18,25,35-42A result of this huge body of research in the
last several years is the “neurotrophin hypothesis of
depression,”which postulates that a decrease in the lev-
els of BDNF plays a major role in the pathophysiology of
depression (and possibly other neuropsychiatric diseases),
and that restoration of its levels may represent a critical
component in the mechanism of antidepressants.
38,39,43,44
Now,while there is no doubt that BDNF may have a pri-
mary role,we find it limiting to restrict the present defin-
ition of the hypothesis to the neurotrophic effect,because
this does not cover all aspects of neuroplasticity.For this
reason we prefer to define the present state of the hypoth-
esis on depression and antidepressant mechanisms
“hypothesis of neuroplasticity,”as addressed above.The
neurotrophic hypothesis is based largely on evidence
showing that stress and depression-related behavior are
associated with reduction of BDNF expression,and that
conversely antidepressant treatments increase BDNF
expression.
38 However,several observations not consis-
tent with this simple framework have been reported:(i)
certain stress paradigms have been found to increase
BDNF expression or to induce complex patterns of reg-
ulation
45-48;(ii) many inconsistent data were produced in
studies with antidepressant treatments (for a discussion
see ref 25);(iii) partial knockout of BDNF in mice did not
produce depression-like behavior, but rather reduced
response to antidepressants
49;(iv) BDNF was shown to
exert opposing roles in hippocampus/cortical areas vs
nucleus accumbens/ventral tegmental area.It was clearly
shown that in these latter areas of the brain reward sys-
tem BDNF (as addressed above for CREB) has a prode-
pressive action.An elegant study by the Nestler group,
using viral-mediated,mesolimbic dopamine pathway-spe-
cific knockdown of BDNF,showed that BDNF is required
for the development of depressive-like behavior induced
by chronic social stress.Effects similar to local knockdown
of BDNF were obtained with chronic administration of
fluoxetine or imipramine.
50 Complementary, a recent
study showed that knockdown of BDNF in hippocampal
dentate gyrus (but not CA1) attenuates the behavioral
response to antidepressants,without inducing depressive-
like behavior.
49
Taken together,these studies suggest that:(i) BDNF may
have anti- or prodepressive function,depending on the
brain areas and circuits;therefore a general increment of
its levels or function in the brain could have nonspecific
and undesired effects;(ii) the involvement of BDNF in
(a) pathophysiology and (b) mechanism of antidepres-
sants,are not necessarily in a simple and direct relation-
ship;behavioral and neurovegetative alterations linked
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in multiple systems and pathways and the BDNF-TrkB
is probably one of the involved pathways, but not the
“essential pathway,”as implied by the lack of depressive-
like behavior in dentate gyrus BDNF knockdown;(iii)
instead BDNF,in the same mice,
49 seems to be necessary
for mediating antidepressant responses.In other words,
even though BDNF is not an essential factor in inducing
depression,potentiation of its function could be essential
for antidepressant mechanism.
39
Modifications of gene expression: the regulation of
BDNF transcription
The BDNF gene has a complex structure that under-
scores its potential for regulation.According to the avail-
able updated nomenclature, the gene encompasses at
least eight noncoding 5’ exons that can be spliced to a
single 3’ exon containing the coding domain for the
BDNF protein, generating 11 different transcripts
according to the last studies.The previous nomenclature
of BDNF transcripts (exons I to V) in the literature cited
below has been translated here to the updated nomen-
clature.
51The regulation of promoter in exon IV has been
extensively characterized.
21,52The functional difference
among the different BDNF transcripts has not been
widely explored thus far but,being among those genes
whose transcripts are translocated to different cellular
compartments,the delivery of different transcripts may
subserve the availability of the message at cell soma,den-
drites,axons,according to the needs of plasticity.
53 Exon
V-containing transcript has been detected in both soma
and dendrites, while exon IV-containing transcript
expression was found to be limited to the cell body.
54 A
number of studies have analyzed the expression of exons
I,II,IV,and V (in the updated nomenclature) in relation
to antidepressant treatments,physical exercise,and stress
paradigms (reviewed in refs 25,39).Interestingly,chronic
defeat stress,a model of depression,has been shown to
downregulate in mouse hippocampus the expression of
BDNF IV and V transcripts, by inducing increased
repressive histone methylation at respective promoters.
55
Chronic imipramine treatment reversed this downregu-
lation and increased histone acetylation at these promot-
ers,a modification associated with chromatin deconden-
sation and facilitation of gene transcription,underscoring
the role of epigenetic mechanisms in stress response and
antidepressant mechanisms.
Recently,we have analyzed for the first time the complete
pattern of expression of the several BDNF transcripts
after treatment with two different antidepressants,fluox-
etine and reboxetine,as an attempt to identify molecular
signatures of different drugs.In hippocampus,fluoxetine
induced BDNF III and IXa and downregulated IV;rebox-
etine induced VI and IXa and downregulated I and IV.
The main difference between the drugs was that fluoxe-
tine selectively induced BDNF III and reboxetine VI.In
prefrontal/frontal cortex fluoxetine induced transiently
(first 2 weeks) BDNF I and VI,and persistently III and
IXa,while it downregulated IV;reboxetine also induced
III and IXa.The main difference here was that fluoxetine,
in addition to the same two transcripts induced by rebox-
etine,transiently induced exons I and VI and downregu-
lated IV (Musazzi et al,unpublished data).Further work
should investigate whether these differences may repre-
sent molecular signatures of distinct drugs.
Synaptic transmission and plasticity: 
mechanisms of antidepressants
Synaptic plasticity encompasses all forms of neuroplastic-
ity that specifically occur at synapses;both functional and
structural forms of plasticity have been described (Table
II).In many cases this term is referred to activity-depen-
dent modifications of the strength or efficacy of synaptic
transmission at glutamate synapses; the most common
forms of long-lasting activity-dependent changes in synap-
tic strength are long-term potentiation (LTP) and long-
term depression (LTD).
56 It has been repeatedly shown
that both stress and antidepressant treatments change
synaptic plasticity (reviewed in refs 3,18,57,58).
Beyond the monoamine hypothesis:
the role of glutamate 
Recent neuroimaging and histopathological studies in
brain of depressed and bipolar patients revealed the pres-
ence of morphometric/functional modifications,including
ventricular enlargement,hippocampal and cortical volu-
metric reduction,and of reduced neurons and glial den-
sity.
59-61 In many of the areas implicated,glutamatergic neu-
rons and synapses predominate,suggesting an involvement
of glutamate neurotransmission in the pathophysiology of
mood disorders.Indeed,in the last few years numerous
lines of evidence have accumulated in favor of a role for
glutamate in psychiatric pathophysiology,including the fol-
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of patients with mood disorders
62-63;(ii) abnormal elevation
of glutamate neurotransmission and glutamate levels in
cortical/limbic brain areas of depressed patients
16,64;(iii)
atrophy of apical dendrites in CA3 hippocampal neurons
induced by chronic stress,a major factor in pathogenesis
of mood disorders
17;(iv) increased amplitude and reduced
decay kinetics of NMDA current induced by chronic
stress
65; (v) impaired long-term potentiation (LTP) and
facilitated depression (LTD) induced by stress.
66
Conversely,antidepressant treatments were also shown to
affect glutamate neurotransmission: (i) antidepressants
downregulate NMDA receptor subunits and dampen
NMDA function
67;(ii) antidepressants may overcome the
effects of stress on LTP
68-69; (iii) chronic antidepressants
reduce depolarization-evoked release of glutamate in hip-
pocampus by modifying presynaptic protein interactions
regulating exocytotic release.
70 Several compounds that
modulate glutamate receptors or glutamate neurotrans-
mission at various levels are under development for the
treatment of mood disorders (depression,bipolar disor-
der,anxiety).
71 Some of these putative drugs may work by
stabilizing glutamate release when its synaptic level
becomes too high,a feature that is now considered as part
of the pathophysiology of mood disorders.
3,15,58,72,73 Recently,
it has been suggested that the effect of antidepressants on
glutamate transmission may also be mediated by increased
AMPA to NMDA throughput in critical neuronal circuits;
this action was suggested to be involved in the rapid anti-
depressant effect of a single ketamine infusion.
74
However,whereas the studies above,as a whole,strongly
suggest that plasticity changes in glutamatergic synapses
are involved both in the pathophysiology of stress-related
diseases and in the action of therapeutic drugs, little is
known as to the cellular and molecular mechanisms
involved.In particular,most of the drugs currently used
for therapy of affective disorders are based on monoamin-
ergic mechanisms, although for some of them a direct
effect on NMDA receptor has been claimed.
67 Knowledge
of the mechanisms whereby drugs interfere with the func-
tion of the glutamatergic synapse would be of great help
in the design of new drugs and therapies.
Synaptic plasticity: the action of antidepressants 
on LTP
It has been repeatedly shown that different experimen-
tal stress protocols (both acute and chronic) impair hip-
pocampal synaptic plasticity,measured as amount of LTP,
the main cellular model of synaptic plasticity.There is
ample literature on this topic,and the reader is addressed
to the numerous reviews available.
18,58,75 However, the
prevalent effect of antidepressants has also been shown
to be a reduction of hippocampal LTP,after acute
68,76-78 or
chronic administration.
79-82 It has been speculated that
antidepressants may induce an LTP-like process which
saturates hippocampal synaptic plasticity,so that capac-
ity for further synaptic change is reduced
83,84;discussed in
ref 58). Interestingly, it has been showed that acute
administration of antidepressants (fluoxetine,
imipramine,tianeptine) may reestablish LTP after acute
stress.
66,67,85 Recently it was shown that the action of
tianeptine (but not of imipramine) could be linked to
reversal of stress-induced down-regulation of
MEK/ERK-MAPK signaling cascade and activation of
Ser831-GluR1 phosphorylation.
86 However,it is difficult
to relate the acute effect on LTP to the therapeutic action
of chronic antidepressants;it will be interesting to assess
how chronic treatments affect stress-induced impairment
of LTP.
Presynaptic mechanisms: the action of antidepressants
Another neuroplasticity-related problem is the effect of
stress and antidepressants on the presynaptic release of
glutamate.Many studies have shown that different para-
digms of stress,or corticosterone administration,induce
a rapid and transient increase of extracellular glutamate
in prefrontal cortex and hippocampus.
87-89 However,in all
these studies the outflow of glutamate was measured by
in vivo microdialysis,a technique that cannot distinguish
between exocytotically released glutamate and metabolic
glutamate.
90 For this reason it has been difficult to relate
exactly the effect of stress to exocytotic glutamate
release.
We have recently approached the problem by measuring
the depolarization-evoked release of glutamate from
freshly purified synaptic terminals (synaptosomes) in
superfusion.
70 First,we reported that chronic (not acute)
treatment with antidepressants endowed with different
primary mechanisms markedly and significantly reduces
depolarization-evoked release of glutamate, but not
release of GABA, from hippocampal synaptosomes.
Interestingly, treatment with the drugs above did not
change the release of glutamate (and GABA) induced
by ionomycin,a calcium ionophore that,contrary to K
+
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releasable pool of vesicles (RRP).Therefore,our results
suggest that antidepressant treatments particularly affect
the release of glutamate from the RRP,thereby altering
a physiologically relevant pool of neurotransmitter.
3,70
Looking for molecular underpinnings of this effect,we
found changes in selected protein-protein interactions
regulating the formation of the core presynaptic 7S
SNARE protein complex, that mediates the fusion of
synaptic vesicles,and a reduction of SNARE complexes
in synaptic membranes (that contain the RRP).These
results suggested that one of the modes of action of anti-
depressants is a stabilization of glutamate release,that
could improve the signal to noise ratio in glutamate neu-
rotransmission, when it becomes compromised by an
excessive release due to the action of stress-related mech-
anisms (iii).As a result,glutamatergic neurotransmission
will be selectively inhibited (release of GABA was not
affected by antidepressants);release of glutamate evoked
by neuronal activation will be decreased in the face of
unchanged constraint exerted by GABA. This would
induce a marked alteration in the balance between exci-
tatory and inhibitory neurotransmission,contributing to
dampening excessive neuronal activation following
stressful stimuli.
91 Our observation that these effects are
measurable only after repeated drug administration is
also in line with the well-known property of these drugs
of being therapeutically efficient only after chronic treat-
ment.
8 We suggest that the remarkable effect of tradi-
tional antidepressants on depolarization-evoked gluta-
mate release in basal conditions could be linked to the
restorative action of these drugs on synaptic plasticity in
hippocampus (HC) and hippocampal/prefrontal cortex
circuits.
68,69
Stress-induced glutamate release: a protective action of
antidepressants?
In order to test whether this mechanism is involved in the
response to stressful events,we subjected the animals to
a standard footshock (FS) stress protocol,similar to that
used to induce learned helplessness,a widely used animal
model of depression,
92 and immediately after the stress
session measured depolarization-evoked release of glu-
tamate from synaptosomes of prefrontal/frontal cortex
(P/FC),obtained from both vehicle and 2-week antide-
pressant-treated rats.
93We found that FS stress induces a
marked and significant (30% to 50%) increase of gluta-
mate release from P/FC synaptosomes,and that acute FS
stress induces accumulation of 7S SNARE complexes in
the synaptic membranes (containing the RRP of gluta-
mate vesicles),a finding in line with increased efficiency
of glutamate release.Previous chronic treatment with dif-
ferent antidepressants (fluoxetine, desipramine) com-
pletely abolished the effect of stress on glutamate release
(Musazzi et al,unpublished data).The molecular under-
pinnings of this drug effect are currently being investi-
gated.Therefore,based on these combined data,we spec-
ulate that modulation of stress-induced release of
glutamate may be a component in the therapeutic mech-
anism of antidepressants in both depression and anxiety.
Postsynaptic glutamate receptors: action of 
antidepressants
Converging evidence suggests that the functional inter-
play between NMDA and AMPA glutamate receptors in
cortical and limbic areas is involved in both the patho-
physiology of mood disorders and in antidepressant
mechanisms.
72-74
The two types of ionotropic glutamate receptors are
often colocalized on the same individual dendritic spines.
It has been clearly demonstrated that the induction of
LTP in the hippocampal CA1 region requires activation
of NMDA receptors,which leads to calcium influx and
activation of downstream signaling.This in turn favors
the recruiting of AMPA receptors to the postsynaptic
membrane, a change that is thought to mediate the
expression of LTP.
56 Several preclinical studies have
shown that chronic treatment with different antidepres-
sants induces a reduction in the function or expression of
the NMDA receptor.Since the early reports on the anti-
depressant action of amantadine,various antidepressants,
including imipramine and citalopram,have been shown
to bind to and inactivate the glycine-binding site of
NMDA receptors.
94 Likewise,functional antagonists of
the NMDA receptor were shown to induce behavioral
changes similar to antidepressants in preclinical screen-
ing tests.Traditional antidepressants have been shown to
produce time- and dose-dependent changes in the radi-
oligand binding properties of rat brain NMDA receptors,
but it is not clear if this is due to downregulation of
receptors, because changes in mRNA expression of
NMDA subunits have been only shown in mice.
95 We
have recently investigated this issue and found that
chronic fluoxetine and reboxetine induce in rat hip-
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NMDA receptor) only locally at synapses, with no
changes in total expression.
96The same result was found
with escitalopram in a genetic animal model of depres-
sion.
82 Therefore, it seems that antidepressant-induced
changes in NMDA receptors are more likely to be found
at synaptic level.
On the other hand,several lines of evidence support the
view that increasing the function of AMPA receptors
may result in antidepressant action. First, it has been
shown that AMPA receptor activation increases the
expression of BDNF (which is a mediator of antidepres-
sant action,see above)
97 as well as stimulating neurogen-
esis.Chronic antidepressant treatments have been shown
to upregulate the membrane insertion of GluR1,
GluR2/3 and synaptic expression of GluR1.
98,99As a con-
sequence, AMPA receptor potentiators (sometimes
called AMPAkines) have been developed as potential
antidepressants (see the final section).
Interestingly, recent clinical studies found a rapid and
sustained antidepressant effect (up to 1 week) of a single
infusion of the noncompetitive NMDA antagonist keta-
mine.
100,101 In a preclinical study Maeng et al
102 showed that
in rats the antidepressant effect (measured in the forced
swim test) may last for 2 weeks.They also showed that
AMPA receptor throughput is required for the antide-
pressant effect of ketamine,and suggested that enhance-
ment of AMPA to NMDA troughput in critical circuits is
the mechanism of rapid antidepressant effect.
102The use
of ketamine for a rapid antidepressant effect has been
proposed as a strategy for treatment-resistant depres-
sion.
74 Intriguingly, acute administration of ketamine
increases glutamate release, probably by disinhibiting
NMDA receptor-containing GABAergic neurons and in
turn enhancing the firing rate of glutamatergic neurons.
But, as addressed above, the prevalent effect of tradi-
tional antidepressants in limbic and cortical areas seems
to be a reduction in glutamate release (particularly if
measured as a response to stress;Musazzi et al,unpub-
lished data); how could this riddle be solved? Early
observations and our preliminary results may suggest
that also traditional antidepressants acutely increase the
presynaptic release of glutamate and that reduction of
glutamate release is an adaptive change which takes time
to develop.
70,103Therefore,in this hypothesis,at the begin-
ning of treatment traditional antidepressants might tran-
siently increase presynaptic glutamate release in critical
circuits (a feature perhaps linked to worsening of symp-
tomatology, eg, anxiety); in the course of treatment,
release of glutamate in limbic/cortical areas,such as hip-
pocampus and prefrontal cortex,will be reduced along
with a synaptic reduction of NMDA receptor levels.This
combined effect would produce a dampening of gluta-
mate transmission and an enhancement of AMPA- vs
NMDA-mediated transmission.More work is required
to understand if this is the mode of action of traditional
antidepressants,and if quicker redistribution of AMPA-
vs NMDA-mediated transmission may speed up the
onset of antidepressant action.
Finally, metabotropic glutamate receptors (mGlu) are
also crucial for the regulation of glutamatergic neuro-
transmission as well as for other neurotransmitters that
are involved in mood disorders and depression.Limited
clinical proof of concept for mGlu receptor ligands in the
treatment of affective disorders has been achieved. In
particular, group II receptor agonists (mGlu2/3) and
group I receptor antagonists (mGlu5) have shown activ-
ity in animal and/or human conditions of fear,anxiety,or
stress.
104
Neurogenesis
The latest addition to the different forms of neuroplas-
ticity was neurogenesis,the generation of new neurons in
the adult brain, whose discovery has broken the long-
standing dogma that the whole neuronal population in
the brain is made up of postmitotic cells.
105,106
Neurogenesis in adult mammalian brain has been so far
described in three areas: the subventricular zone, hip-
pocampal dentate gyrus, and olfactory bulb, although
there are reports that it may also occur in cerebral cor-
tex and hypothalamus. It has been estimated that in
rodent brain approximately 250 000 new neurons, and
about 6% of the granule cell layer, are formed each
month.
107 However,in primates this number seems to be
much smaller,and it is still debated whether this lower
rate of neurogenesis is clinically significant in pathology
and in the action of psychotropics.A number of magnetic
resonance imaging studies have clearly shown that hip-
pocampal volume may be reduced in depressed patients
and that this correlates with recurrence and length of
depressive episodes.
108 Although it has been suggested
that reduced neurogenesis might be a contributing fac-
tor,there is at present no clear evidence supporting this
hypothesis.On the contrary the available evidence sug-
gests reduction of neuropil and loss of glial cells as main
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394factors in the shrinking of hippocampus in depression.
109
However,compelling evidence from preclinical studies
showed that different paradigms of stress reduce hip-
pocampal neurogenesis,while antidepressant treatments
and interventions that have antidepressant properties,
such as physical exercise or environmental enrichment,
increase neurogenesis (reviewed in ref 108).To date,the
most convincing evidence for a role of neurogenesis in
the mechanism of antidepressants was offered by a study
in which the knockout of 5-HT1A receptor,or restricted
irradiation of the subgranular zone,suppressed neuroge-
nesis and at the same time the behavioral effects of flu-
oxetine and imipramine in mice.
110Two later studies sup-
ported the same conclusion.
Studies in which adult hippocampal neurogenesis was
blocked did not show increased anxiety-related behavior
or increased susceptibility to the effects of chronic stress,
as assayed in preclinical sceens (reviewed in ref 111).For
this reason,based on the available evidence,it is likely
that neurogenesis in the hippocampus is probably not a
major contributor to the etiology of depression,although
it may be required for the behavioral effects of antide-
pressants.Future imaging studies allowing to visualize
hippocampal neurogenesis are warranted to understand
the role of adult neurogenesis.
Future directions: new targets for 
antidepressants
As summarized in Figure I,all the available antidepres-
sants are based on acute mechanisms affecting
monoaminergic transmission. Although, as addressed
above, there is ample evidence that different and con-
verging downstream mechanisms are responsible for
therapeutic effect of these drugs,no drug based on non-
monoaminergic mechanism has made it to the market so
far.The reasons for this are multiple and have been ana-
lyzed in recent reviews.
3,10,112We believe that four factors
have been particularly important for the lack of success
in the development of new drugs for psychiatric disor-
ders:(i) lack of adequate diagnostic classification;(ii) lack
of adequate animal models;(iii) lack of adequate trans-
lational work;(iv) problems in target validation.
First,the present diagnostic and classification system in
psychiatry is based on arrays of symptoms,rather than on
neurobiology, epidemiology, genetics, or response to
treatments.A primary goal in this area is the develop-
ment of a diagnostic system based on these different
aspects, rather than on the phenomenology of the dis-
ease.This is especially timely if one takes into account the
recent progress in the knowledge of genetic factors,psy-
chosocial stressors, and most important gene-environ-
ment interactions in predisposing for pathology.
113
Second,we still lack adequate animal models of depres-
sion and/or anxiety. Most available models are either
based on the exposure of “normal”animals to different
paradigms of acute or chronic stress,or they are straight-
forward knockouts for some of the genes that have been
involved in depression.Obviously,depressed patients are
not gene knockouts;they carry different combinations of
gene mutations that (most probably through multiple
gene interactions) may combine with adverse life events
predisposing for disease.Therefore,what is needed is the
development of animal models carrying known human
mutations or noncharacterized genetic vulnerability (but
with good face,construct,and predictive validity),sub-
jected to validated stress paradigms.
82,113,114 What seems
crucial is to reproduce to some extent the gene-environ-
ment interaction that is believed to be central to human
depression.Third,there is a lack of sufficient translational
efforts applying recent neuroscience research findings
and technology to pharmacology and biological psychia-
try. In spite of the great development of research on
postreceptor signaling cascades,gene expression,epige-
netic mechanisms,synaptic plasticity,identification of bio-
markers for vulnerability and drug response/resistance
by global genomics/proteomics, a large part of current
pharmaceutical research is still focused on the stereotype
“receptor-ligand”interaction.As a consequence,several
recent “novel”drugs in psychiatry are still compounds
acting on neurotransmitter receptors or transporters.
Although the trend has been changing lately,still a good
part of the new basic knowledge needs to be applied to
or interfaced with target discovery/validation and clini-
cal research.Fourth,target validation is still one of the
main problems in psychiatric pharmacology,because in
most cases ultimate validation is missing or may be
obtained only when the drug is already on the market.To
be added to the previous,a fifth,not strictly scientific,rea-
son was the lack of stimulus from major pharmaceutical
companies to take the risks involved in developing new
nonmonoaminergic drugs for depression. Differently
from other drug fields (eg, cancer, cardiovascular dis-
eases) much of the effort in recent times was directed
toward replication and implementation of already known
mechanisms (eg,“me-too”drugs).
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number of new compounds are in development.We have
listed here only new drug classes that have been in devel-
opment for some time (some of them for quite a long
time) and possibly recent new drugs will be missing here.
Most of these compounds are based on peptidergic,glu-
tamatergic or circadian rhythm-related mechanisms,but
a few still relate to a monoaminergic mechanism (Table
III).
NK-1 receptor and CRF-1 receptor antagonists have had
a somewhat troubled history.Both drug classes have in
turn raised much hope and most companies have had
(some still have) these compounds in their pipeline.In
the case of NK-1 antagonists,one of them (MK-869) did
not separate from placebo in phase II clinical studies and
the development was discontinued. However, the
hypothesis of using NK-1 antagonists for add-on strategy
with SSRIs or SNRIs is still pursued.Antagonists of the
CRF1 receptor have also been in development for quite
some time.After preclinical development,one of these
compounds (R121919) showed antidepressant efficacy in
an open-label clinical trial,but later was dropped owing
to hepatotoxicity.Other compounds in this class are still
in development.
Compounds acting on glutamate transmission represent
a large and variegated class of potential antidepressants.
71
As addressed above,the interest in glutamate as a poten-
tial target in depression and mood disorder is not new;
however,recently this interest was revived by several key
findings,such as the many morphological and functional
changes found with depression in areas where glutamate
transmission predominates, the documented effects of
stress on glutamatergic neurons and circuits,the striking
sustained antidepressant effect of a single infusion of ket-
amine (see above).The psychotomimetic properties of
ketamine are a limit to its clinical use,but similar com-
pounds less endowed with these properties would be
interesting drugs that could greatly fasten the onset of
action.Weaker NMDA antagonists,such as memantine,
or compounds acting on modulatory sites of the NMDA
receptor could be viable alternatives to reduce NMDA-
mediated throughput.Another possibility is interfering
with glutamate release,which could be upregulated after
acute or chronic stress; drugs that have a reduction of
glutamate release as component of their mechanism of
action are already on the market (riluzole,lamotrigine).
A feasible strategy of limiting glutamate release could be
the use of ligands for metabotropic receptors,that could
be safer than compounds directly affecting the machin-
ery of release.AMPAkines,drugs potentiating the func-
tion of AMPA receptors have also been in development
for some time. Tianeptine, an antidepressant that has
been for some years in the market, has shown unique
properties in the regulation of neuroplasticity,and this
effect seems to be mediated by its modulation of the glu-
tamatergic system.
116-119
A novel approach to depression,regulation of circadian
rhythms, has been the basis for the development of an
antidepressant with an entirely new mechanism of action.
Changes in the sleep-wake cycle and in the periodicity of
circadian rhythm profoundly influence the state of mood.
Sleep disturbances and depression/mood disorders are
interlinked.
120Among the typical and recurring features
of depressed individuals is insomnia with early-morning
awakenings;indeed,disturbed sleep is one of the diag-
nostic criteria in DSM-IV.Likewise,it has been shown
that manipulations of circadian rhythms,such as total or
REM sleep deprivation or phase advance in the sleep-
wake cycle,may have therapeutic action in the treatment
of depression.
121 It is not clear whether sleep disturbances
are part of the clinical picture of depression or represent
a causative factor;some studies have shown that changes
in sleep architecture persist into the remission phase,
while improvement in clinical state is frequently pre-
ceded by sleep changes.
120,121 The first (and so far only)
antidepressant in this class is agomelatine,an agonist of
MT1/MT2 melatonergic receptors and antagonist of sero-
tonin 5-HT2C receptor. Agomelatine was shown to
induce resynchronization of circadian rhythms and to be
efficient in preclinical studies with different animal mod-
els of depression.The antidepressant efficacy of the drug
in humans was positively tested in several clinical trials,
122
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New nonmonoamine-based antidepressants. 
• NK-1 receptor antagonists
• CRF1 antagonists
• Glutamatergic agents (NMDA blockers, AMPAkines, 
mGlu modulators, riluzole, lamotrigine)
• Melatonergic (MT1/2) agonist / 5-HT2C antagonist (agomelatine)
New monoamine-based antidepressants
• 5-HT4 and 5-HT6 agonists
• 5-HT7 antagonists
Table III. New antidepressants in development or marketed. NK, neu-
rokinin; NMDA, N-methyl-D-aspartic acid; CRF, corticotrophin-
releasing factor; AMPA, alpha-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid; mGlun glutamate; 5-HT, serotoninand its regulation of the sleep-wake cycle has been
proven.
123,124 A recent study of long-term (10 months)
treatment showed efficacy of agomelatine against
placebo, while the percentage of patients reporting
adverse effects was similar in the two groups.
125
Furthermore,it presents clinical benefits such as respect
of sexual function,absence of discontinuation symptoms,
and no effect on body weight.
126,127Agomelatine could be
the first antidepressant with a really new mechanism of
action to hit the market which will also achieve a better
quality of remission by directly acting on the residual
symptoms.
Finally, among the novel compounds in development
there are also a few monoamine-based putative antide-
pressants, namely agonists or antagonists of the most
recently characterized subtypes of serotonin receptors,
5-HT4,5-HT6,and 5-HT7 (Table II).
Conclusion
Overall, the monoamine hypothesis of depression and
antidepressant mechanisms has become,over nearly half
a century, a hypothesis of neuroplasticity.We are able
today to identify new targets for antidepressants with
nonmonoaminergic mechanisms.As a result,there are a
good number of such compounds in development,which,
in the treatment of mood disorders,gives hope for novel,
more effective,and safer antidepressants. ❏
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Mecanismos celulares y moleculares en la
acción a largo plazo de los antidepresivos
Las hipótesis acerca de la fisiopatología de los tras-
tornos del ánimo y la depresión, y de los mecanismos
antidepresivos han cambiado mucho en los últimos
años. La clásica hipótesis monoaminérgica mostró ser
simplista, en cuanto a que no podía explicar el
retardo temporal en la acción terapéutica de los anti-
depresivos. Líneas convergentes de evidencia han
mostrado que los cambios de adaptación en varios
mecanismos de neuroplasticidad son probablemente
los correlatos celulares y moleculares del efecto tera-
péutico.  En este artículo se analizan algunos meca-
nismos de neuroplasticidad en relación con el meca-
nismo de los antidepresivos, que van desde cambios
en la expresión génica (incluyendo mecanismos neu-
rotróficos) hasta la transmisión sináptica y la plastici-
dad, y la neurogénesis. Se propone que la versión
actual de la hipótesis del mecanismo de los antide-
presivos sea llamada simplemente la “hipótesis de la
neuroplasticidad”. En la sección final se revisan bre-
vemente las principales estrategias actuales en la far-
macología de la depresión y los nuevos blancos para
los antidepresivos, con especial énfasis en los meca-
nismos no monoaminérgicos. 
Mécanismes cellulaires et moléculaires dans
l’action à long terme des antidépresseurs
Les hypothèses sur la physiopathologie des troubles
dépressifs/de l’humeur et sur les mécanismes anti-
dépresseurs ont bien changé ces dernières années.
L’hypothèse classique monoaminergique s’est révé-
lée simpliste, car elle ne peut expliquer le délai d’ac-
tion des antidépresseurs. Des preuves convergentes
indiquent que plusieurs mécanismes adaptatifs de
la neuroplasticité semblent être des corrélats cellu-
laires et moléculaires de l’effet thérapeutique. Dans
cet article, plusieurs mécanismes de neuroplasticité
sont analysés en relation avec le mécanisme des
antidépresseurs, s’échelonnant entre les modifica-
tions de l’expression du gène (y compris les méca-
nismes neutrophiques), jusqu’à la neurogenèse, et
la plasticité et la transmission synaptiques. Nous
proposons que la version actuelle de l’hypothèse du
mécanisme antidépresseur s’appelle simplement «
l’hypothèse de la neuroplasticité ». Au dernier cha-
pitre, nous revoyons aussi rapidement les princi-
pales stratégies actuelles dans la pharmacologie de
la dépression et les nouvelles cibles généralement
admises des antidépresseurs, en insistant particuliè-
rement sur les mécanismes non monoaminergiques.Translational research
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